Combating acquired resistance to trastuzumab by an anti-ErbB2 fully human antibody

Trastuzumab resistance is a common problem that impedes the effectiveness of trastuzumab in ErbB2-amplified cancers. About 70% of ErbB2-amplified breast cancers do not respond to trastuzumab (de novo resistance), and the majority of the trastuzumab-responsive cancers progress within 1 year (acquired...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chao, Wang, Lingfei, Yu, Xiaojie, Zhang, Yajun, Meng, Yanchun, Wang, Huajing, Yang, Yang, Gao, Jie, Wei, Huafeng, Zhao, Jian, Lu, Cuihua, Chen, Han, Sun, Yanping, Li, Bohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522102/
https://www.ncbi.nlm.nih.gov/pubmed/28514745
http://dx.doi.org/10.18632/oncotarget.17451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522102/
https://www.ncbi.nlm.nih.gov/pubmed/28514745
http://dx.doi.org/10.18632/oncotarget.17451

Ejemplares similares